Helicobacter pylori (H pylori) infection is among the most common bacterial infections worldwide with approximately one-half of the world’s population infected. Several invasive and noninvasive testing methods are available to detect H pylori infection.
Several multiplex molecular assays have been developed for the detection of gastrointestinal pathogens directly from clinical stool samples. These panels allow for the detection and identification of up to 20 pathogens in as little as one hour. A recent review published in the Journal of Clinical Microbiology focuses on the FDA-cleared multiplex molecular panels for the diagnosis of diarrheal disease and highlights issues related to test performance, result interpretation, and cost-effectiveness of these molecular diagnostic tools.
Chronic Hepatitis C Treatment and Monitoring Algorithm: Interferon-Free Combination Therapy [Algorithm]
Up to 30 percent of patients with diarrheal irritable bowel syndrome (IBS) also suffer from bile acid malabsorption (BAM). Recently, a new test was introduced that can identify BAM from a stool sample. In this “Hot Topic,” Leslie Donato, Ph.D., will describe a new test for probing the etiology of this condition.
Diagnosis of idiopathic duct-centric chronic pancreatitis (IDCP), also known as type 2 autoimmune pancreatitis, requires pancreatic histology and/or concurrent inflammable bowel disease. In a recent study published in the journal Gut, Mayo Clinic researchers examined past experience with IDCP to assess the appropriateness of this criteria, and identify unique characteristics in patients presenting with acute pancreatitis.
The new Infliximab Quantitation with Reflex to Antibodies to Infliximab, Serum, test is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients. This test should be ordered to assess a trough level quantitation for evaluation of patients with loss of response to infliximab.